Humana Inc. is a for-profit American health insurance company based in Louisville, Kentucky.
| Revenue (TTM) | $145.68B |
| Gross Profit (TTM) | $19.89B |
| EBITDA | $3.60B |
| Operating Margin | 3.46% |
| Return on Equity | 6.89% |
| Return on Assets | 3.90% |
| Revenue/Share (TTM) | $1211.44 |
| Book Value | $160.00 |
| Price-to-Book | 2.43 |
| Price-to-Sales (TTM) | 0.32 |
| EV/Revenue | 0.371 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 27.10% |
| Quarterly Revenue Growth (YoY) | 26.20% |
| Shares Outstanding | $120.08M |
| Float | $119.81M |
| % Insiders | 0.21% |
| % Institutions | 101.61% |
Volatility is currently expanding
Joel Greenblatt's Gotham Asset Management disclosed a defensive tilt in its Q2 2026 13F, filed in mid-August, headlined by a $2.65 billion add to the SPDR S&P 500 ETF and outsized conviction buys in managed care, packaged foods, and Manhattan office real estate.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
HUM's HealthStream deal backs 1,000 caregiver scholarships and new tools to improve recruitment and retention in Indiana.
Health insurer Humana has agreed not to refer to drugmaker Teva as an Israeli company at an upcoming U.S. drug price-fixing trial, after the drugmaker said public views on the Gaza war could unfairly influence jurors.
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced that James “J.P.” Holland will join the company as senior vice president and President of Medicaid, effective August 17. In this role, Holland will lead the company's growing Medicaid business, which currently serves more than 1.6 million members in 11 states. Holland will report to Aaron Martin, President of Insurance. “Medicaid is an important part of how we deliver on Humana's purpose, helping some of the most vulnerab.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Humana NYSE: HUM said its 2026 performance is tracking in line with expectations, with management emphasizing planned Medicare Advantage margin expansion in 2027, progress in its Stars program and continued operating-cost reductions as key components of its path toward a sustainable pretax margin of at least 3% in 2028.
Humana Inc. targets a sustainable 3% pre-tax margin by 2028, focusing on Medicare Advantage plan quality and operational efficiency. Despite robust revenue growth, HUM's profit margins have sharply declined, with Q2 2026 pre-tax margin at 1.8%, down from 6.7% in 2020. Management remains committed to margin recovery via improved Stars ratings, cost reductions, and selective plan exits, aiming for top-quartile performance.
Pre-market futures are flat-to-down ahead of today's open, with overseas turbulence in the memory chip market reverberating on domestic shores. We also see something of a hesitation in trading ahead of this afternoon's Fed decision on interest rates.
HUM's Q2 earnings top estimates as medical membership growth, premium gains and CenterWell strength lift results despite higher costs.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HUM and any ticker you trade — then tracks every position and per-strategy win rate.
